Date:             October 26, 2018

Source:         American Academy of Ophthalmology
Summary:    A new study shows that an implantable delivery system for a widely used medication to treat a blinding eye disease has enabled some patients to go 15 months in between treatments. This represents a vast improvement over the typical regimen of nearly monthly eye injections.